Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency

American Journal of Kidney Diseases

Volumn 36, Issue 6, 2000, Pages 1207-1212

  Townsend, Raymond R ^a,b,c,d,e,f   Cohen, Debbie L ^a,b,c,d,e,f   Katholi, Richard ^a,b,c,d,e,f   Swan, Suzanne K ^a,b,c,d,e,f   Davies, Brian E ^a,b,c,d,e,f   Bensel, Kathy ^a,b,c,d,e,f   Lambrecht, Larry ^a,b,c,d,e,f   Parker, John ^a,b,c,d,e,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Prairie Cardiovascular Consultants Ltd   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d Total Renal Research Inc   (United States)

^e Advanced Biomedical Research   (United States)

^f Bracco Research USA   (United States)

Author keywords

Chronic renal failure (CRF); Contrast agent; Gadolinium

Indexed keywords

CREATININE; GADOLINIUM BENZYLOXYPROPIONIC ACETATE DIMEGLUMINE; GADOLINIUM DERIVATIVE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INFUSION; KIDNEY FUNCTION; MALE; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

EID: 0033659992     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.19836     Document Type: Article

References (26)

1. Contrast-medium-induced acute renal failure
2. Risk factors and outcome of hospitalacquired acute renal failure. Clinical epidemiologic study
3. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial
4. Renal function impairment caused by intravenous urography
5. Nephrotoxicity of high-osmolality versus low-osmolality contrast media: Randomized clinical trial
6. Nephrotoxic risks of renal angiography: Contrast-media associated nephrotoxicity and atheroembolism - A critical review
7. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography
8. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure
9. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast
10. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience
11. GD-DOTA: Evaluation of its renal tolerance in patients with chronic renal failure
12. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment
13. Measurement of renal function in chronic renal disease
14. Safety of gadolinium-DTPA: Extended clinical experience
15. Safety assessment of gadopentetate dimeglumine in US clinical trials
16. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure
17. Renal lesion characterization with gadolinium-enhanced MR imaging: Efficacy and safety in patients with renal insufficiency
18. The relationship between thermodynamics and the toxicity of gadolinium complexes
19. Gadobenate dimeglumine (Gd-BOPTA). An overview
20. Multihance clinical pharmacology: Biodistribution and MR enhancement of the liver
21. Gadolinium chelates with weak binding to serum proteins. A new class of high efficiency, general purpose contrast agents for magnetic resonance imaging
22. Gadopentetate dimeglumine: A possible alternative contrast agent for CT angiography of the aorta
23. Use of gadopentetate dimeglumine as a contrast agent for percutaneous transluminal renal angioplasty and stent placement
24. Renal insufficiency: Gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures
25. Gadopentetare dimeglumine as an alternative contrast agent for use in interventional procedures
26. Arterial angiography in high kilovoltage technique with gadolinium as the contrast agent. First clinical experience